Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine

被引：0
|
作者：
Ailani, J. [1 ]
Gandhi, P. [2 ]
Lalla, A. [3 ]
Singh, R. B. Halker [4 ]
McAllister, P. [5 ]
Smith, J. H. [6 ]
Dabruzzo, B. [2 ]
Chalermpalanupap, N. [2 ]
Nahas, S. J. [7 ]
机构：
[1] MedStar Georgetown Univ Hosp, Washington, DC USA
[2] AbbVie, Madison, NJ USA
[3] AbbVie, Irvine, CA USA
[4] Mayo Clin, Scottsdale, AZ USA
[5] New England Inst Neurol & Headache, Stamford, CT USA
[6] AbbVie, N Chicago, IL USA
[7] Thomas Jefferson Univ, Dept Neurol, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P051
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Network Meta-analysis on Monthly Migraine Day Reductions With Fremanezumab, Rimegepant, and Atogepant in the Prevention of Episodic Migraine
    Silberstein, S. D.
    Cohen, J. M.
    Driessen, M.
    Muresan, B.
    Krasenbaum, L. J.
    Johnston, A.
    Seminerio, M. J.
    Carr, K.
    Akcicek, H.
    Dever, J.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 2):
  • [22] Cost-Effectiveness Evaluation of Oral CGRP Antagonists, Atogepant and Rimegepant, for the Preventative Treatment of Episodic Migraine: Results from a US Societal Perspective Model
    Ryan Thaliffdeen
    Anthony Yu
    Karen Rascati
    Clinical Drug Investigation, 2024, 44 : 209 - 217
  • [23] Atogepant, the first oral preventive treatment for chronic migraine
    Haanes, Kristian A.
    Edvinsson, Lars
    LANCET, 2023, 402 (10404): : 748 - 749
  • [24] SECUKINUMAB VS. ADALIMUMAB FOR TREATMENT OF ANKYLOSING SPONDYLITIS: A COST PER RESPONDER ANALYSIS AT 52 WEEKS FROM AN ARGENTINIAN PERSPECTIVE
    Barbeau, M.
    Bianculli, P. M.
    Nikoglou, E.
    Gunda, P.
    Jugl, S. M.
    MacPherson, A.
    VALUE IN HEALTH, 2017, 20 (09) : A535 - A535
  • [25] SECUKINUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: A COST PER RESPONDER ANALYSIS AT 48 WEEKS FROM A BRAZILIAN PERSPECTIVE
    Lopes, N.
    Suzuki, C.
    Barbeau, M.
    MacPherson, A.
    Jugl, S. M.
    VALUE IN HEALTH, 2017, 20 (09) : A938 - A938
  • [26] Atogepant for the Preventive Treatment of Migraine in Participants With Prior Treatment Failure: The ELEVATE Trial
    Pozo-Rosich, P.
    Nagy, K.
    Tassorelli, C.
    Lanteri-Minet, M.
    Sacco, S.
    Nezadal, T.
    Finnegan, M.
    Guo, H.
    Gandhi, P.
    Trugman, J.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 212 - 213
  • [27] Effect of Atogepant on Headache Impact Test-6 Among Individuals With Episodic Migraine and Preventive Treatment Failure
    Tassorelli, C.
    Gandhi, P.
    Sacco, S.
    Pozo-Rosich, P.
    Lanteri-Minet, M.
    Nezadal, T.
    Trugman, J.
    Luo, L.
    Stokes, J.
    Nagy, K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 215 - 216
  • [28] Rimegepant for the acute and preventive treatment of migraine: a narrative review of the evidence
    Edvinsson, Lars
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2024,
  • [29] Erenumab as a first line preventive treatment for episodic migraine in Spain: a cost-effectiveness analysis
    Irimia, P.
    Sanchez, S.
    Crespo, C.
    Martinez, M.
    Pozo-Rosich, P.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [30] Preventive Oral Treatment of Episodic Migraine: An Overview
    Ranganathan, Lakshmi N.
    Ramamurthy, Guhan
    Kanthimathinathan, Shunmugasundaram
    NEUROLOGY INDIA, 2021, 69 : S51 - S58
12345